Search Results for "Infection"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Infection. Results 81 to 90 of 242 total matches.

Antiviral Drugs for COVID-19 in Vaccinated Outpatients

   
The Medical Letter on Drugs and Therapeutics • Mar 06, 2023  (Issue 1671)
COVID-19 and mortality in high risk patients. Clin Infect Dis 2023; 76:e342. 4. NR Aggarwal et al ...
Three products are currently available in the US for treatment of high-risk,1 nonhospitalized adults with mild to moderate COVID-19: oral ritonavir-boosted nirmatrelvir (Paxlovid), IV remdesivir (Veklury), and oral molnupiravir (Lagevrio). Remdesivir is FDA-approved for such use; nirmatrelvir/ritonavir and molnupiravir are available under an FDA Emergency Use Authorization. Because the pivotal clinical trials of these products for outpatient use were conducted in patients who were not vaccinated against COVID-19, some clinicians have questioned whether they can benefit vaccinated...
Med Lett Drugs Ther. 2023 Mar 6;65(1671):33-4   doi:10.58347/tml.2023.1671a |  Show IntroductionHide Introduction

Ritlecitinib (Litfulo) for Severe Alopecia Areata

   
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023  (Issue 1690)
warning about an increased risk of serious infections, malignancies (particularly lymphomas), major ...
The FDA has approved ritlecitinib (Litfulo – Pfizer), an oral JAK and TEC kinase family inhibitor, for treatment of severe alopecia areata in patients ≥12 years old. Ritlecitinib is the second oral drug to be approved in the US for treatment of severe alopecia areata; baricitinib (Olumiant), a JAK inhibitor, is approved only for use in adults.
Med Lett Drugs Ther. 2023 Nov 27;65(1690):185-6   doi:10.58347/tml.2023.1690a |  Show IntroductionHide Introduction

Vonoprazan (Voquezna) for Erosive Esophagitis

   
The Medical Letter on Drugs and Therapeutics • Dec 25, 2023  (Issue 1692)
and clarithromycin (Voquezna Triple Pak) for treatment of Helicobacter pylori infection in adults.1 GERD ...
The FDA has approved vonoprazan (Voquezna – Phathom), a potassium-competitive acid blocker, for healing and maintenance of healing of all grades of erosive esophagitis and relief of associated heartburn in adults. Vonoprazan is also available copackaged with amoxicillin (Voquezna Dual Pak) and with amoxicillin and clarithromycin (Voquezna Triple Pak) for treatment of Helicobacter pylori infection in adults.
Med Lett Drugs Ther. 2023 Dec 25;65(1692):203-5   doi:10.58347/tml.2023.1692b |  Show IntroductionHide Introduction

Mirikizumab (Omvoh) for Ulcerative Colitis

   
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024  (Issue 1698)
: Infections, injection-site reactions, arthralgia, rash, and headache are most common. Anaphylaxis ...
The FDA has approved the interleukin (IL)-23 antagonist mirikizumab-mrkz (Omvoh – Lilly) for treatment of moderately to severely active ulcerative colitis (UC) in adults. Mirikizumab is the first selective IL-23 antagonist to be approved for this indication. Ustekinumab (Stelara), an IL-12/23 antagonist, was approved for treatment of UC in 2019. The IL-23 antagonist risankizumab (Skyrizi) is approved for treatment of Crohn's disease.
Med Lett Drugs Ther. 2024 Mar 18;66(1698):46-7   doi:10.58347/tml.2024.1698c |  Show IntroductionHide Introduction

Risankizumab (Skyrizi) for Ulcerative Colitis

   
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024  (Issue 1715)
-site reactions, and rash. It can also increase the risk of infection. Serious hypersensitivity ...
The injectable interleukin (IL)-23 antagonist risankizumab-rzza (Skyrizi – Abbvie), previously approved by the FDA for treatment of Crohn's disease (CD), has now been approved for treatment of moderately to severely active ulcerative colitis (UC) in adults. Risankizumab is the first IL-23 antagonist to be approved for treatment of both CD and UC. It is also approved for treatment of plaque psoriasis and psoriatic arthritis.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):182-4   doi:10.58347/tml.2024.1715d |  Show IntroductionHide Introduction

Oteseconazole (Vivjoa) for Recurrent Vulvovaginal Candidiasis

   
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022  (Issue 1656)
% of RVVC infections and are less susceptible to standard treatment. Resistance to azole antifungals ...
The FDA has approved oteseconazole (Vivjoa – Mycovia), a new oral azole antifungal, to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC. Oteseconazole is the first drug to be approved in the US specifically for treatment of RVVC.
Med Lett Drugs Ther. 2022 Aug 8;64(1656):124-6 |  Show IntroductionHide Introduction

Upadacitinib (Rinvoq): A Second JAK Inhibitor for Ulcerative Colitis

   
The Medical Letter on Drugs and Therapeutics • Sep 05, 2022  (Issue 1658)
were upper respiratory tract infection, blood creatine phosphokinase increases, acne, neutropenia ...
The FDA has approved the oral Janus kinase (JAK) inhibitor upadacitinib (Rinvoq – Abbvie) for treatment of moderately to severely active ulcerative colitis in adults who have had an inadequate response to or cannot tolerate one or more tumor necrosis factor (TNF) inhibitors. Upadacitinib is the second JAK inhibitor to be approved for this indication; tofacitinib (Xeljanz) was the first. Upadacitinib is also approved for treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and ankylosing spondylitis.
Med Lett Drugs Ther. 2022 Sep 5;64(1658):142-4 |  Show IntroductionHide Introduction

Rozanolixizumab (Rystiggo) for Myasthenia Gravis

   
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024  (Issue 1696)
living compared to addition of placebo. Adverse Effects: Headache is the most common. Infections ...
Rozanolixizumab-noli (Rystiggo – UCB), a neonatal Fc receptor (FcRn) blocker, has been approved by the FDA for treatment of generalized myasthenia gravis in adults with anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. It is the first drug to be approved for treatment of generalized myasthenia gravis in patients with anti-MuSK antibodies. Four other biologic drugs – the FcRn blocker efgartigimod alfa (Vyvgart; Vyvgart Hytrulo) and the complement inhibitors eculizumab (Soliris), ravulizumab (Ultomiris), and zilucoplan (Zilbrysq) – are...
Med Lett Drugs Ther. 2024 Feb 19;66(1696):29-31   doi:10.58347/tml.2024.1696c |  Show IntroductionHide Introduction

An EUA for Baricitinib (Olumiant) for COVID-19

   
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020  (Issue 1614)
sheet) in 1033 hospitalized adults with confirmed SARS-CoV-2 infection and either radiographic ...
The oral Janus kinase (JAK) inhibitor baricitinib (Olumiant – Lilly) has been granted an FDA Emergency Use Authorization (EUA) for treatment of confirmed or suspected COVID-19 in hospitalized patients ≥2 years old who require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO); the EUA requires that baricitinib be used in combination with the IV antiviral drug remdesivir (Veklury). Baricitinib has been available for treatment of rheumatoid arthritis since 2018. Remdesivir was recently approved by the FDA for treatment of COVID-19 in...
Med Lett Drugs Ther. 2020 Dec 28;62(1614):202-3 |  Show IntroductionHide Introduction

Cantharidin Topical Solution (Ycanth) for Molluscum Contagiosum

   
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024  (Issue 1696)
― A skin infection caused by a poxvirus, molluscum contagiosum is most common in preschool ...
The FDA has approved cantharidin 0.7% solution (Ycanth – Verrica) for topical treatment of molluscum contagiosum in patients ≥2 years old. Ycanth was the first drug to be approved in the US for this indication. A 10.3% gel formulation of berdazimer (Zelsuvmi), a nitric oxide-releasing agent, has also been approved by the FDA for treatment of molluscum contagiosum (in patients ≥1 year old); it will be reviewed in a future issue.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):27-9   doi:10.58347/tml.2024.1696b |  Show IntroductionHide Introduction